Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.66 USD
Change Today -0.22 / -7.64%
Volume 977.9K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Alan G. Harris M.D., Ph.D., FACP FRCP

Vice President of Regenerative Medicine, Drug Development & Regulatory Affairs, Neostem, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 board members in 1 different organizations across 4 different industries.

See Board Relationships
63--

Background*

Dr. Alan G. Harris, M.D. Ph.D. FACP FRCP has been Vice President of Regenerative Medicine Drug evelopment and Regulatory Affairs at Neostem Inc. since July 2009. Dr. Harris serves as an Officer of Ophthalmic Imaging Systems Inc. Dr. Harris served as Chief Medical Officer of Immune Pharmaceuticals Corp. since September 2011. Dr. Harris was responsible to develop Bertilimumab, company's phase II ready fully human monoclonal antibody for Crohn's Disease and lcerative Colitis ...

Read Full Background

Corporate Headquarters*

420 Lexington Avenue
New York, New York 10170

United States

Phone: 212-584-4180
Fax: 646-514-7787

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

PhD
Erasmus University
MD
Université de Strasbourg

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $2.66 USD -0.22

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
$599.8K
Robin C. Stracey Interim Chief Executive Officer and Director
Cesca Therapeutics Inc.
--
Marc H. Hedrick M.D.Chief Executive Officer, President, Director and Member of Executive Committee
Cytori Therapeutics, Inc.
$437.4K
Martin M. McGlynn Chief Executive Officer, Director, Member of Strategic Transactions Committee, Chief Executive Officer of Stemcells California Inc and President of Stemcells California Inc
StemCells Inc.
$789.5K
Martin P. Rosendale Chief Executive Officer and Director
Nuo Therapeutics, Inc.
$385.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.